

# Myron E Schwartz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6756613/publications.pdf>

Version: 2024-02-01

277  
papers

39,622  
citations

8208

78  
h-index

3100

193  
g-index

279  
all docs

279  
docs citations

279  
times ranked

32498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
2	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
3	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24
4	Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. <i>Hpb</i> , 2022, 24, 470-477.	0.1	4
5	Left lateral segment pediatric liver transplantation: a 25 year experience at Mount Sinai. <i>Hpb</i> , 2022, 24, 817-824.	0.1	2
6	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 219-229.	3.7	79
7	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	15.2	12
8	Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. <i>European Radiology</i> , 2022, 32, 6493-6503.	2.3	5
9	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. <i>Abdominal Radiology</i> , 2022, 47, 969-980.	1.0	11
10	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	3.2	19
11	Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 505.	3.7	0
12	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
13	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	3.6	42
14	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	6.1	57
15	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
16	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
17	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
18	Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 122-132.	2.0	19

#	ARTICLE	IF	CITATIONS
19	PD-1 inhibitor as bridge therapy to liver transplantation?. American Journal of Transplantation, 2021, 21, 1979-1980.	2.6	69
20	Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatology International, 2021, 15, 459-471.	1.9	1
21	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver International, 2021, 41, 1922-1932.	1.9	15
22	Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. Journal of Pain and Symptom Management, 2021, 61, 940-947.e3.	0.6	10
23	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	1.5	15
24	Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. Annals of Surgery, 2021, 274, 780-788.	2.1	72
25	Abstract 64: Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, , .		1
26	Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. Cancer Research, 2021, 81, CT182-CT182.	0.4	3
27	N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes. Molecular Cancer Research, 2021, 19, 1868-1877.	1.5	21
28	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020). Gastroenterology, 2021, 161, 879-898.	0.6	123
29	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Reports, 2021, 3, 100364.	2.6	9
30	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	5.8	21
31	Early effect of 90Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. European Radiology, 2021, 31, 5791-5801.	2.3	6
32	685...Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, 9, A713-A713.		0
33	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. American Journal of Transplantation, 2020, 20, 220-230.	2.6	33
34	Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. European Radiology, 2020, 30, 1020-1030.	2.3	45
35	Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. Hpb, 2020, 22, 677-689.	0.1	35
36	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 1729-1738.e1.	0.2	27

#	ARTICLE	IF	CITATIONS
37	Assessment of Hepatocellular Carcinoma Response to <sup>90</sup> Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. <i>Radiology Imaging Cancer</i> , 2020, 2, e190094.	0.7	15
38	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. <i>Journal of Hepatology</i> , 2020, 73, S28-S29.	1.8	0
39	Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. <i>Cancer Medicine</i> , 2020, 9, 4962-4970.	1.3	78
40	Modern management of splenomegaly in patients with myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 1441-1451.	0.8	15
41	Inpatient Palliative Care Consultation Is Associated with Lower Hazard of Readmission for Patients with Hepatocellular Carcinoma (RP506). <i>Journal of Pain and Symptom Management</i> , 2020, 60, 231-232.	0.6	0
42	Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Liver Cancer</i> , 2020, 9, 138-147.	4.2	25
43	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
44	Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. <i>Cancer Imaging</i> , 2020, 20, 43.	1.2	23
45	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 3759-3769.	2.3	97
46	Advances in resection and transplantation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 262-276.	1.8	107
47	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
48	Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. <i>Liver Transplantation</i> , 2020, 26, 888-898.	1.3	21
49	The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2020, 59, 940-943.	0.8	4
50	Abdominal Tuberculosis Mimicking Cancer Clinically and on Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Imaging: A Two-Case Series. <i>American Journal of Case Reports</i> , 2020, 21, e918901.	0.3	8
51	Von Meyenburg complexes: a rare intrahepatic bile duct malformation. <i>Minerva Surgery</i> , 2020, 75, 272-274.	0.1	0
52	A novel online calculator to predict perioperative blood transfusion in patients undergoing liver resection for hepatocellular carcinoma: an international multicenter study. <i>Hpb</i> , 2020, 22, 1711-1721.	0.1	5
53	Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn's Disease: A 9-Year Survival. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	1
54	Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 1497-1504.	0.1	30

#	ARTICLE	IF	CITATIONS
55	Intrathecal Morphine Administration Does Not Affect Survival After Liver Resection for Hepatocellular Carcinoma. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2019, 23, 309-318.	0.4	4
56	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
57	HIV infection modulates IL-1 $\beta$ response to LPS stimulation through a TLR4-NLRP3 pathway in human liver macrophages. <i>Journal of Leukocyte Biology</i> , 2019, 105, 783-795.	1.5	16
58	Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 367-374.	0.6	0
59	Outcomes After Differing Surgical Strategies in Patients With Small Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, e50-e51.	0.5	2
60	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
61	Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: A multicenter study. <i>Surgery</i> , 2019, 165, 516-524.	1.0	28
62	Surgery for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: The cornerstone but not the only stone. <i>American Journal of Surgery</i> , 2019, 217, 192.	0.9	0
63	Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, e15644-e15644.	0.8	0
64	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
65	Outcomes of resection for solitary $\leq 5$ cm intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2018, 163, 698-702.	1.0	21
66	Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study. <i>American Journal of Surgery</i> , 2018, 215, 125-130.	0.9	19
67	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 734-740.	0.6	22
68	Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn's Disease: A Case with Prolonged Survival. <i>American Journal of Gastroenterology</i> , 2018, 113, S1176-S1177.	0.2	0
69	At Diagnosis of Hepatocellular Carcinoma, African Americans With Hepatitis C Have Better Liver Function Than Other Patients. <i>Clinical Liver Disease</i> , 2018, 12, 109-112.	1.0	6
70	Perioperative Management in Hepatic Resections: Comparative Effectiveness of Neuraxial Anesthesia and Disparity of Care Patterns. <i>Anesthesia and Analgesia</i> , 2018, 127, 855-863.	1.1	2
71	Is it Time to Abandon the Milan Criteria?. <i>Annals of Surgery</i> , 2018, 268, 690-699.	2.1	87
72	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64

#	ARTICLE	IF	CITATIONS
73	Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. <i>Frontiers in Oncology</i> , 2018, 8, 220.	1.3	11
74	Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 920-926.	0.2	13
75	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	1.8	120
76	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
77	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
78	Comparison of Patterns and Outcomes of Liver Resection for Hepatocellular Carcinoma: East vs West. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1972-1974.	2.4	17
79	Renal cell carcinoma with inferior vena cava thrombus extending to the right atrium diagnosed during pregnancy. <i>Therapeutic Advances in Urology</i> , 2017, 9, 155-159.	0.9	5
80	Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 161-168.	0.7	17
81	Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1083-1090.	1.5	38
82	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 1222-1231.	1.8	121
83	Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 805-811.	0.4	21
84	Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. <i>Pancreas</i> , 2016, 45, 528-532.	0.5	2
85	Disentangling the effects of race and socioeconomic factors on liver transplantation rates for hepatocellular carcinoma. <i>Clinical Transplantation</i> , 2016, 30, 714-721.	0.8	33
86	Closure of an iatrogenic gastrogastric fistula created during EUS-directed transgastric ERCP. <i>VideoGIE</i> , 2016, 1, 61-62.	0.3	8
87	917 Taking the EDGE off. <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB184-AB185.	0.5	0
88	Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 812-821.e2.	0.2	44
89	Expanded Criteria for Resection: Are Current Guidelines Too Conservative?. <i>Current Hepatology Reports</i> , 2016, 15, 323-326.	0.4	3
90	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863

#	ARTICLE	IF	CITATIONS
91	Idiopathic perinatal hepatic infarct as a cause of liver mass. <i>Annals of Pediatric Surgery</i> , 2016, 12, 167-169.	0.1	0
92	Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e133-e137.	0.2	10
93	Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. <i>Clinical Imaging</i> , 2016, 40, 897-901.	0.8	7
94	Reply to "Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: A cautionary comment". <i>Journal of Hepatology</i> , 2016, 65, 229-230.	1.8	0
95	Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 583-593.	1.8	105
96	Reporting and methodological qualities of published surgical meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 4-16.	2.4	32
97	Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores. <i>Anticancer Research</i> , 2016, 36, 399-402.	0.5	3
98	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
99	Recurrence of Hepatocellular Cancer After Resection. <i>Annals of Surgery</i> , 2015, 261, 947-955.	2.1	576
100	Perioperative Blood Transfusion and Long-Term Outcomes After Resection of Hilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1192-1193.	0.9	0
101	Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. <i>Hepatology</i> , 2015, 61, 895-904.	3.6	105
102	Surgical management of noncirrhotic portal hypertension. <i>Clinical Liver Disease</i> , 2015, 5, 112-115.	1.0	7
103	Prognostic Significance of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2015, 101, 58-65.	1.2	40
104	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	5.8	240
105	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
106	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	1.8	64
107	Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage Oâ€œB1 Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2015, 110, 595.	0.2	2
108	Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4073-4085.	3.2	97

#	ARTICLE	IF	CITATIONS
109	Outcomes following resection of intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2015, 17, 344-351.	0.1	60
110	Transplantation for hepatocellular carcinoma: More haste, less speed?. <i>Hepatology</i> , 2015, 62, 1327-1328.	3.6	0
111	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	7.0	278
112	The role of hepatic resection in the treatment of hepatocellular cancer. <i>Hepatology</i> , 2015, 62, 440-451.	3.6	310
113	Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1630-1638.	0.2	9
114	Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 650-658.	2.1	77
115	Perspective: Incision revision. <i>Nature</i> , 2014, 516, S17-S17.	13.7	1
116	Histological Changes in Nontumoral Liver Secondary to Radioembolization of Hepatocellular Carcinoma with Yttrium 90-impregnated Microspheres: Report of Two Cases. <i>Seminars in Liver Disease</i> , 2014, 34, 465-468.	1.8	6
117	Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. <i>Targeted Oncology</i> , 2014, 9, 145-153.	1.7	70
118	Metzenbaum-Assisted Liver Resection: A Safe and Effective Liver Resection Technique. <i>Digestive Surgery</i> , 2014, 31, 312-317.	0.6	4
119	Actual 10-year survival following hepatectomy for hepatocellular carcinoma. <i>Hpb</i> , 2014, 16, 830-835.	0.1	34
120	Current management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 10223.	1.4	61
121	Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression. <i>Blood</i> , 2014, 124, 1871-1871.	0.6	0
122	Resection of Hepatocellular Carcinoma with Macroscopic Vascular Invasion. <i>Annals of Surgical Oncology</i> , 2013, 20, 3754-3760.	0.7	69
123	Resection or transplant listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. <i>Hpb</i> , 2013, 15, 134-141.	0.1	20
124	Resection of hepatocellular cancer $\leq 2$ cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
125	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	3.6	0
126	Surgical Resection for Hepatocellular Carcinoma in the Noncirrhotic: The Western Experience. <i>Recent Results in Cancer Research</i> , 2013, 190, 85-100.	1.8	6



#	ARTICLE	IF	CITATIONS
127	Resection of Hepatocellular Carcinoma Without Cirrhosis. <i>Annals of Surgery</i> , 2012, 255, 1135-1143.	2.1	52
128	Carcinoma Ex Microcystic Adenoma of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 305-310.	2.1	23
129	Hepatic Resection for Primary Hepatolithiasis: A Single-Center Western Experience. <i>Journal of the American College of Surgeons</i> , 2012, 215, 622-626.	0.2	55
130	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
131	Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). <i>Gastrointestinal Endoscopy</i> , 2012, 76, 293-300.	0.5	24
132	Diaphragmatic Hernia After Hepatic Resection: Case Series at a Single Western Institution. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1910-1914.	0.9	21
133	Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases. <i>PLoS ONE</i> , 2012, 7, e36979.	1.1	59
134	Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 3888-3899.	3.9	74
135	Recurrent giant hemangiomas of liver: Report of two rare cases with literature review. <i>World Journal of Gastrointestinal Surgery</i> , 2012, 4, 262.	0.8	4
136	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
137	Second hepatic resection for recurrent hepatocellular cancer: A Western experience. <i>Journal of Hepatology</i> , 2011, 55, 346-350.	1.8	58
138	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
139	The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. <i>Transplant International</i> , 2011, 24, 243-250.	0.8	28
140	Prognostic Clinicopathologic Factors in Longitudinally Followed Patients With Metastatic Small Bowel Carcinoid Tumors. <i>Pancreas</i> , 2011, 40, 1253-1257.	0.5	15
141	Cholangiolocellular Carcinoma: An Innocent-Looking Malignant Liver Tumor Mimicking Ductular Reaction. <i>Seminars in Liver Disease</i> , 2011, 31, 104-110.	1.8	36
142	Functional abdominal complaints occurred frequently in living liver donors after donation. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 611-615.	0.6	3
143	Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas. <i>Liver International</i> , 2010, 30, 996-1002.	1.9	18
144	Primary Hepatic Signet Ring Cell Neuroendocrine Tumor: A Case Report with Literature Review. <i>Seminars in Liver Disease</i> , 2010, 30, 422-428.	1.8	15

#	ARTICLE	IF	CITATIONS
145	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211
146	Surgical resection for advanced gallbladder carcinoma. The Mount Sinai experience. <i>Hepato-Gastroenterology</i> , 2010, 57, 1005-12.	0.5	2
147	The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies. <i>Cancer Research</i> , 2009, 69, 2514-2522.	0.4	493
148	Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1 $\alpha$ -mediated stellate cell activation. <i>Hepatology</i> , 2009, 49, 2055-2067.	3.6	132
149	Trefoil factor-3 expression in human colon cancer liver metastasis. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 143-151.	1.7	38
150	Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?. <i>Annals of Surgical Oncology</i> , 2009, 16, 379-384.	0.7	73
151	Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. <i>Cardiovascular Pathology</i> , 2009, 18, 243-246.	0.7	22
152	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
153	A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 850-855.	0.6	517
154	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
155	Utility of Lens culinaris Agglutinin-Reactive Fraction of $\alpha$ -Fetoprotein and Des-Gamma-Carboxy Prothrombin, Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 104-113.	2.4	113
156	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	0.7	249
157	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
158	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
159	Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. <i>Journal of Hepatology</i> , 2008, 49, 581-588.	1.8	80
160	Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. <i>American Journal of Surgery</i> , 2008, 196, 160-169.	0.9	87
161	Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 698-711.	3.0	1,545
162	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148

#	ARTICLE	IF	CITATIONS
163	Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 630-631.	4.3	9
164	Multiple Inflammatory and Serum Amyloid A Positive Telangiectatic Hepatic Adenomas with Glycogenated Nuclei Arising in a Background of Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2008, 28, 434-439.	1.8	9
165	Strategies for the management of hepatocellular carcinoma. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 424-432.	4.3	253
166	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	1.8	75
167	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	3.6	632
168	Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin. <i>Journal of the American College of Surgeons</i> , 2007, 205, S93-S94.	0.2	0
169	Liver Transplantation: the Preferred Treatment for Early Hepatocellular Carcinoma in the Setting of Cirrhosis?. <i>Annals of Surgical Oncology</i> , 2007, 14, 548-552.	0.7	250
170	The role of fibrin sealants in hepatic surgery. <i>Surgical Technology International</i> , 2007, 16, 31-6.	0.1	7
171	De Novo Hepatocellular Carcinoma Occurring in a Transplanted Liver: Case Report and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1780-1782.	1.1	19
172	Liver Transplantation for Liver Rupture Due to Light Chain Deposition Disease: A Case Report. <i>Seminars in Liver Disease</i> , 2006, 26, 298-303.	1.8	17
173	Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There. <i>Seminars in Liver Disease</i> , 2006, 26, 248-253.	1.8	29
174	Marked Differences in Acute Cellular Rejection Rates between Living-Donor and Deceased-Donor Liver Transplant Recipients. <i>Transplantation</i> , 2005, 80, 1072-1080.	0.5	41
175	Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. <i>Hepatology</i> , 2005, 42, 1420-1428.	3.6	45
176	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	1.8	1,043
177	Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-2a upon Progression. <i>Oncologist</i> , 2005, 10, 718-727.	1.9	35
178	How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. <i>Journal of Hepatology</i> , 2005, 43, 584-589.	1.8	69
179	Invasive Colloid Carcinoma Arising from Intraductal Papillary Neoplasm in a 50-Year-Old Woman with Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2004, 24, 209-213.	1.8	14
180	Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of Post Administration ALT Elevation. <i>American Journal of Transplantation</i> , 2004, 4, 1805-1809.	2.6	54

#	ARTICLE	IF	CITATIONS
181	Anatomic variations in right liver living donors1 1No competing interests declared.. Journal of the American College of Surgeons, 2004, 198, 577-582.	0.2	148
182	Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery, 2004, 8, 208-212.	0.9	120
183	Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease*. Clinical Transplantation, 2004, 18, 94-99.	0.8	134
184	The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation1. Clinical Transplantation, 2004, 18, 152-155.	0.8	37
185	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40, 1047-1052.	3.6	142
186	Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transplantation, 2004, 10, 534-540.	1.3	403
187	Adultâ€“adult living donor liver transplantation. Journal of Gastrointestinal Surgery, 2004, 8, 303-312.	0.9	12
188	Unresectable Squamous Cell Carcinoma of Donor Origin Treated With Immunosuppression Withdrawal and Liver Replantation. American Journal of Transplantation, 2004, 4, 278-282.	2.6	16
189	BILIARY COMPLICATIONS IN 96 CONSECUTIVE RIGHT LOBE LIVING DONOR TRANSPLANT RECIPIENTS. Transplantation, 2004, 77, 1842-1848.	0.5	212
190	Adult Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma. Annals of Surgery, 2004, 239, 142-149.	2.1	185
191	Giant hemangioma of the adrenal. Israel Medical Association Journal, 2004, 6, 705-6.	0.1	3
192	Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. Journal of the American College of Surgeons, 2003, 197, 765-769.	0.2	21
193	Treatment Strategies for Hepatocellular Carcinoma in Cirrhosis. Journal of Gastrointestinal Surgery, 2003, 7, 401-411.	0.9	20
194	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. American Journal of Gastroenterology, 2003, 98, 2060-2063.	0.2	165
195	Epsteinâ€“Barr virus and human hepatocellular carcinoma. Cancer Letters, 2003, 192, 49-57.	3.2	23
196	Candidate selection criteria for living donor liver transplantation. Mount Sinai Journal of Medicine, 2003, 70, 171-3.	1.9	6
197	Long-Term Results With Multimodal Adjuvant Therapy and Liver Transplantation for the Treatment of Hepatocellular Carcinomas Larger Than 5 Centimeters. Annals of Surgery, 2002, 235, 533-539.	2.1	368
198	Quality of life after lobectomy for adult liver transplantation1. Transplantation, 2002, 73, 1593-1597.	0.5	127

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. <i>Lancet Oncology</i> , The, 2002, 3, 593-603.	5.1	242
200	Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 237-241.	2.0	52
201	Hepatocellular Carcinoma A Prime Indication for Living Donor Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 102-107.	0.9	75
202	An Integrated Approach to Intestinal Failure Results of a New Program With Total Parenteral Nutrition, Bowel Rehabilitation, and Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 554-562.	0.9	55
203	Post-traumatic pseudoaneurysm of the common hepatic artery with duodenal fistula. <i>Hpb</i> , 2002, 4, 183-186.	0.1	13
204	One Hundred Nine Living Donor Liver Transplants in Adults and Children: A Single-Center Experience. <i>Annals of Surgery</i> , 2001, 234, 301-312.	2.1	289
205	ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON'S DISEASE. <i>Transplantation</i> , 2001, 72, 1232-1236.	0.5	114
206	Use of intraoperative Doppler ultrasound to diagnose hepatic venous obstruction in a right lobe living donor liver transplant. <i>Liver Transplantation</i> , 2001, 7, 547-550.	1.3	13
207	Intratumoral Adenovirus-Mediated Suicide Gene Transfer for Hepatic Metastases from Colorectal Adenocarcinoma: Results of a Phase I Clinical Trial. <i>Molecular Therapy</i> , 2001, 4, 182-191.	3.7	104
208	CRITICAL GRAFT SIZE IN ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION: THE IMPACT OF THE RECIPIENT'S DISEASE.. <i>Transplantation</i> , 2000, 69, S290.	0.5	6
209	INTESTINAL TRANSPLANTATION WITH LYMPHOCYTOXIC CROSSMATCHING.. <i>Transplantation</i> , 2000, 69, S184.	0.5	0
210	Retransplantation for late liver graft failure: Predictors of mortality. <i>Liver Transplantation</i> , 2000, 6, 174-179.	1.3	94
211	Central nervous system complications in liver transplant recipients - incidence, timing, and long-term follow-up. <i>Clinical Transplantation</i> , 2000, 14, 1-7.	0.8	192
212	IFN $\gamma$ secretion following stimulation with total tumor peptides from autologous human tumors. <i>Journal of Immunological Methods</i> , 2000, 241, 61-68.	0.6	4
213	Liver Transplantation for Autoimmune Hepatitis. <i>Hepatology</i> , 2000, 32, 693-700.	3.6	155
214	Comparison of Surgical Outcomes for Hepatocellular Carcinoma in Patients With Hepatitis B Versus Hepatitis C: A Western Experience. <i>Annals of Surgical Oncology</i> , 2000, 7, 764-770.	0.7	101
215	Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. <i>American Journal of Gastroenterology</i> , 2000, 95, 1535-1538.	0.2	166
216	Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients. <i>Mediators of Inflammation</i> , 2000, 9, 141-146.	1.4	11

#	ARTICLE	IF	CITATIONS
217	Expression of p53 and PCNA in Cholangiocarcinoma and Primary Sclerosing Cholangitis. <i>Modern Pathology</i> , 2000, 13, 1265-1268.	2.9	51
218	Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. <i>Transplant International</i> , 2000, 13, 73-78.	0.8	38
219	A 67-Year-Old Man with Hepatitis C Virus Infection and a Liver Tumor. <i>Seminars in Liver Disease</i> , 2000, 20, 227-232.	1.8	4
220	ACCURACY AND SIGNIFICANCE OF COMPUTED TOMOGRAPHIC SCAN ASSESSMENT OF HEPATIC VOLUME IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 545-550.	0.5	109
221	LIVER TRANSPLANTATION IN A PATIENT WITH ACUTE LIVER FAILURE DUE TO SICKLE CELL INTRAHEPATIC CHOLESTASIS. <i>Transplantation</i> , 2000, 69, 675-677.	0.5	52
222	LONG-TERM MEDICAL COMPLICATIONS IN PATIENTS SURVIVING 5 YEARS AFTER LIVER TRANSPLANT. <i>Transplantation</i> , 2000, 69, 781-789.	0.5	245
223	A 42-Year-Old Woman with Liver Masses and Long-Term Use of Oral Contraceptives. <i>Seminars in Liver Disease</i> , 1999, 19, 339-344.	1.8	14
224	Correlation between von Willebrand factor levels and early graft function in clinical liver transplantation. <i>Clinical Transplantation</i> , 1999, 13, 25-31.	0.8	10
225	Living related liver transplantation for acute liver failure in children. <i>Liver Transplantation</i> , 1999, 5, 161-165.	1.9	68
226	Transmission of factor VII deficiency through liver transplantation. <i>Transplant International</i> , 1999, 12, 278-280.	0.8	7
227	SAFE TRANSPLANTATION OF BLOOD TYPE A2 LIVERS TO BLOOD TYPE O RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 1999, 67, 1071-1073.	0.5	37
228	Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. <i>Journal of the American College of Surgeons</i> , 1998, 187, 365-372.	0.2	125
229	The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 1998, 28, 831-838.	3.6	212
230	Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. <i>American Journal of Gastroenterology</i> , 1998, 93, 2148-2153.	0.2	19
231	Donor des-gamma-carboxy prothrombin positivity is a risk factor for poor early graft function in liver transplantation. <i>Transplant International</i> , 1998, 11, 143-146.	0.8	3
232	Higher Incidence of Diabetes in Liver Transplant Recipients With Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 30-33.	1.1	123
233	New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. <i>BioDrugs</i> , 1997, 8, 469-488.	2.2	15
234	Assessment of Liver Allograft Function by Hyaluronic Acid and Endothelin Levels. <i>Journal of Surgical Research</i> , 1997, 73, 123-128.	0.8	20

#	ARTICLE	IF	CITATIONS
235	Effluent levels of thrombomodulin predict early graft function in clinical liver transplantation. <i>Liver</i> , 1997, 17, 224-229.	0.1	16
236	USE OF LIVERS WITH MICROVESICULAR FAT SAFELY EXPANDS THE DONOR POOL. <i>Transplantation</i> , 1997, 64, 248-251.	0.5	242
237	EFFICACY OF TACROLIMUS AS RESCUE THERAPY FOR CHRONIC REJECTION IN ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 64, 258-263.	0.5	92
238	SELECTIVE REVASCULARIZATION OF HEPATIC ARTERY THROMBOSES AFTER LIVER TRANSPLANTATION IMPROVES PATIENT AND GRAFT SURVIVAL <sup>1</sup> . <i>Transplantation</i> , 1997, 64, 1295-1299.	0.5	127
239	Persistent Hypersplenism Early After Liver Transplant. <i>Transplantation</i> , 1997, 64, 1481-1483.	0.5	17
240	INCREASED RISK OF EARLY REJECTION CORRELATES WITH RECOVERY OF CD3 CELL COUNT AFTER LIVER TRANSPLANT IN PATIENTS RECEIVING OKT3 INDUCTION <sup>1</sup> . <i>Transplantation</i> , 1997, 64, 1214-1216.	0.5	1
241	Hepatocellular carcinoma in long-term oral contraceptive use. <i>Liver</i> , 1996, 16, 372-376.	0.1	13
242	SAFE USE OF HEPATIC ALLOGRAFTS FROM DONORS OLDER THAN 70 YEARS <sup>1</sup> . <i>Transplantation</i> , 1996, 62, 62-65.	0.5	159
243	N-ACETYLCYSTEINE AMELIORATES REPERFUSION INJURY AFTER WARM HEPATIC ISCHEMIA. <i>Transplantation</i> , 1995, 59, 6-9.	0.5	82
244	SUCCESSFUL USE OF AN ENHANCED IMMUNOSUPPRESSIVE PROTOCOL WITH PLASMAPHERESIS FOR ABO-INCOMPATIBLE MISMATCHED GRAFTS IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 986-990.	0.5	53
245	BACKTABLE RESECTION OF A GIANT CAVERNOUS HEMANGIOMA IN A DONOR LIVER. <i>Transplantation</i> , 1995, 60, 616.	0.5	8
246	Management of Hepatic Adenoma in Glycogen Storage Disease Ia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1995, 20, 225-228.	0.9	13
247	LIVER TRANSPLANTATION IN A PATIENT WITH HIGH COLD AGGLUTININ TITERS. <i>Transplantation</i> , 1995, 60, 622-623.	0.5	3
248	Detection of Hepatitis B and Hepatitis C Viral Sequences in Fulminant Hepatic Failure of Unknown Etiology. <i>American Journal of Clinical Pathology</i> , 1995, 104, 588-593.	0.4	23
249	Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. <i>Hepatology</i> , 1995, 21, 30-34.	3.6	353
250	Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein. <i>Liver</i> , 1995, 15, 30-34.	0.1	18
251	Loss of speech after orthotopic liver transplantation. <i>Transplant International</i> , 1995, 8, 234-237.	0.8	13
252	High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation. <i>Transplant International</i> , 1995, 8, 152-156.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. <i>Hepatology</i> , 1995, 21, 30-34.	3.6	36
254	Primary Hepatocellular Carcinoma: Transplant Versus Resection. <i>Seminars in Liver Disease</i> , 1994, 14, 135-139.	1.8	19
255	OBVIATION OF PREREPERFUSION RINSING AND DECREASE IN PRESERVATION/REPERFUSION INJURY IN LIVER TRANSPLANTATION BY PORTAL BLOOD FLUSHING <sup>1</sup> . <i>Transplantation</i> , 1994, 57, 799-802.	0.5	33
256	DIABETOGENICITY OF FK506 VERSUS CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1994, 58, 370-371.	0.5	5
257	ACUTE HEPATIC FAILURE IN SEVEN PATIENTS AFTER PROPHYLAXIS AND THERAPY WITH ANTITUBERCULOUS AGENTS. <i>Transplantation</i> , 1994, 58, 372-376.	0.5	0
258	REVERSAL OF SEVERE FK506 SIDE EFFECTS BY CONVERSION TO CYCLOSPORINE-BASED IMMUNOSUPPRESSION. <i>Transplantation</i> , 1994, 58, 380-381.	0.5	2
259	Early Graft-Sigmoid Erosion in a Patient with Prior Sigmoid Resection—A Case Report. <i>Vascular Surgery</i> , 1993, 27, 240-241.	0.3	0
260	Liver Resection Under Total Vascular Isolation Variations on a Theme. <i>Annals of Surgery</i> , 1993, 217, 15-19.	2.1	94
261	THE ARCUATE LIGAMENT SYNDROME IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1993, 56, 223.	0.5	25
262	FK506 VERSUS CYCLOSPORINE AS PRIMARY IMMUNOSUPPRESSIVE AGENT FOR ORTHOTOPIC LIVER ALLOGRAFT RECIPIENTS HISTOLOGIC AND IMMUNOPATHOLOGIC OBSERVATIONS <sup>1</sup> . <i>Transplantation</i> , 1993, 56, 1389-1393.	0.5	25
263	PROLONGED PRESERVATION IN UNIVERSITY OF WISCONSIN SOLUTION ASSOCIATED WITH HEPATIC ARTERY THROMBOSIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1993, 56, 1399-1402.	0.5	65
264	Transplant Recipients Seletion: Peacetime vs. Wartime Triage. <i>Cambridge Quarterly of Healthcare Ethics</i> , 1992, 1, 327-331.	0.5	59
265	EVIDENCE THAT THE SYSTEMATIC ANALYSIS OF BILE CYTOLOGY PERMITS MONITORING OF HEPATIC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1992, 54, 471-474.	0.5	9
266	Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. <i>Hepatology</i> , 1992, 16, 949-955.	3.6	143
267	Endoscopic color Doppler assessment of portal and hepatic vasculature after orthotopic liver transplantation. <i>Gastrointestinal Endoscopy</i> , 1991, 37, 190-191.	0.5	2
268	Use of the superficial femoral vein as a replacement for large veins. <i>Journal of Vascular Surgery</i> , 1991, 13, 460-461.	0.6	7
269	Angiomyolipoma of the liver: immunohistochemical study of a case. <i>Liver</i> , 1991, 11, 158-161.	0.1	22
270	RESISTANT HEPATIC ALLOGRAFT REJECTION SUCCESSFULLY TREATED WITH CYCLOPHOSPHAMIDE AND PLASMAPHERESIS. <i>Transplantation</i> , 1990, 50, 702-703.	0.5	9



#	ARTICLE	IF	CITATIONS
271	Arteriovenous Fistula Following Punch-Graft Hair Transplantation. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1989, 15, 754-755.	0.8	14
272	Therapeutic Alternatives in Primary Aortic Salmonellosis—A Case Report. <i>Vascular Surgery</i> , 1989, 23, 485-490.	0.3	0
273	Treatment of ischemia due to [ldquo ]steal[rdquo ] by arteriovenous fistula with distal artery ligation and revascularization. <i>Journal of Vascular Surgery</i> , 1988, 7, 770-773.	0.6	196
274	Wound complications after in situ bypass. <i>Journal of Vascular Surgery</i> , 1988, 7, 802-807.	0.6	74
275	Unusual venous thrombosis associated with protein C deficiency. <i>Journal of Vascular Surgery</i> , 1988, 7, 443-445.	0.6	0
276	Postoperative intussusception after vaginal vault suspension. <i>American Journal of Obstetrics and Gynecology</i> , 1986, 154, 633-634.	0.7	6
277	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 571-581.	1.8	10